Despite being present in only <10% of de novo AML cases among younger patients [2], mutant TP53 is present in up to 30% of treatment-related AML cases [3] and ~60% of AML cases with complex karyotype (CK) (i.e., AML containing ≥3 genetic aberrations) [2,3] and 20% of elderly patients [4]. This evidence concerns the gene TP53 and acute myeloid leukemia.